M edicare'si mpacto nm anaged care andt he private market hasdramaticallyincreased as more payers offer coverage andc aref or Medicare beneficiaries through Medicare Part D. This growingi nfluence hasc reated newp rocesses,promptingapush-and-pullinterplaybetween public and privatepoliciesthatisunlikelytoresolve in thenearfuture. The direct effectsofpublicand privatepoliciesand practicesappearto have reciprocaleffects, more so todaythaninthe past.Thisarticle will examinet raditional Medicare coverage of cancert herapies, Medicare reform,MedicarePartD ,and theimplicationso fall of thesefor providersand cancerpatients, with an emphasisonthe differences in public andp rivate approaches. Specific examples usedwill relate to colorectal cancer( CRC).
M edicare'si mpacto nm anaged care andt he private market hasdramaticallyincreased as more payers offer coverage andc aref or Medicare beneficiaries through Medicare Part D. This growingi nfluence hasc reated newp rocesses,promptingapush-and-pullinterplaybetween public and privatepoliciesthatisunlikelytoresolve in thenearfuture. The direct effectsofpublicand privatepoliciesand practicesappearto have reciprocaleffects, more so todaythaninthe past.Thisarticle will examinet raditional Medicare coverage of cancert herapies, Medicare reform,MedicarePartD ,and theimplicationso fall of thesefor providersand cancerpatients, with an emphasisonthe differences in public andp rivate approaches. Specific examples usedwill relate to colorectal cancer( CRC).
Previous articles have discussed infusion therapiesa nd theb righter, more promisingh orizon foro rala ntineoplastics. Althoughthe fieldo fo ncologywill continue to rely on andwelcome new infusionp roducts, oncologyp ractitioners arel ooking forwardt othe numerous oral products in theresearchp ipeline. Managingexistingand soon-to-be approvedo ralantineoplastics will create financial,administrative, andutilization management challengesi ng eneral,e speciallywithin thec ontext of Medicare Part D.
■■ TheBurden of ColorectalCancer
Medicare's need to address CRCi sl argely basedo nt he volume of patients affected;C RC is thes econd leadingc ause of cancer deathinthe United States.Because this diseasegenerallyaffects people aged 50 years or older andt he mean agea td iagnosis is 72 years,m ost affected Americansare Medicare-eligible. 1 As the "babyb oomers"a ge,the number of andb urdenassociatedwith Medicare-insured CRCp atientsw ill continue to rise.H ence, Medicare hasbeendiligently working to establishaway to manageCRC appropriately,not only clinicallybut also financially, so that allb eneficiaries have appropriate access to thei mproving standard of care.Medicareprovidescoveragefor more than 50% of all cancerpatients, andmanyprivate payers follow,orborrow significantly from,M edicare'sp oliciesf or coverage of andp ayment forcancercare.
Currently, Medicare is as ignificantp ayerf or CRC( see Figure) . It pays for6 2% of costsa ssociatedw ithi npatientC RC care and4 9% of all outpatientC RC care,o fw hich 15%i sp rovidedinhospitaloutpatientdepartments and85% in physician's offices. Medicare's typicalbeneficiary with CRCcan be expected to be amongthe oldest andsickest of CRCpatients. 2 Discussion of Medicare in anyc ontext is oftenf acilitatedi ft he "parts" (e.g., the"entitled"PartAand theoptionalParts B, C, andnow D) areexplained.T able 1describes Medicare coverage. In most cases, Medicare beneficiaries receive Part Ac overage on ap remium-freeb asis.P arts B, C, andDs upplementP artA coverage andare optional benefitsrequiringseparate premiums. Medicare'sregulations covering cancerare statute-based; if medicallyr easonablea nd necessary, Medicare must provider eimbursement fora nticancera gentsb ased on thea gents' U.S. Food andD rugA dministration( FDA)-approvedl abeling. Statutory languageinSection1 861(t)(1)and (2)o fthe Social Security Act provides Medicare reimbursement foro ff-label indicationso f products in chemotherapeutic regimens as well,and foroff-label prescribing, ap racticet hati sf requentlyu sedi nt he oncology field. Thep rovisionsa re straightforward: theo ff-label use must be supported by 1ormoreofthe compendialisted in thestatute, whichare discussed furtherbelow,o rthe carrier involved must determine thatt he treatmenti sm edically acceptedb ased on peer-reviewedsupportiveclinicalevidenceappearing in publicationsa si dentifiedb yt he Secretaryo ft he U.S. Department of Health andH uman Services (HHS). Compendiaa re critical for applying Medicare's off-labelcoveragepolicybecause of howthe statutoryl anguaged efines itsu se.T he importance of thec ompendia also extendst othe privateinsurance industry.H owever, with significant variationa mong andwithinp rivate payers,t he privatemarketdoesnot use compendiainthe consistentmanner thatMedicared oes. Some privatepayers use compendialistings alongwiththeir ownpharmacyand therapeutics reviews, which ofteni nclude primaryl iteraturer eviews,c linicald ata, and primaryinformation from drug manufacturers. 3, 4 Thus,t ou nderstandc overagep oliciesf or Medicare beneficiaries, health care providerso ften referencec ompendial istings or locate literature that supports thec ancerd iagnosis they are treating. Thecurrent Medicare-approved compendiainclude the United States Pharmacopeia Drug Information( USP-DI)a nd theA merican Hospital FormularyS ervice Drug Information (AHFS-DI). Medicare carriers generallyu se both compendia in theirc overaged ecision-making processes andt oc onfirm information foundineach. It is importanttonotethatanegative listinginone of therecognizedcompendiawill trumpapositive listinginanother andpotentiallyresultinnoncoverage. 4 In addition to theUSP-DIand AHFS-DI, othercompendiaare petitioningtobeincludedinMedicare'slistofapproved compendia. One, theNationalComprehensiveCancerNetwork(NCCN) Drugsa nd BiologicsC ompendium,i sb ecomingi ncreasingly important. An ationallyr ecognizedg roup,N CCNi sa ctively involved in creatingand disseminatingevidence-basedand consensus guidelines forc ancerc are. This compendium delineates usesofdrugs andbiologics in thecareofcancerpatients,listing FDA-approvedd isease indicationsa nd specific NCCN recommendations foruse as well as defininglevelsofevidenceand categorieso fc onsensus-supportingr ecommendations.O ther drug referencesources,including DRUGDEXSystem, thecompendium usedbyMedicaidagencies, and Facts&Comparisons and Clinical Pharmacology ,a re also seekingf ormalr ecognition andC MS approvala sp arto ft he compendiap rocess within thec overage determination.
■■ Pathways to Coverage
CMSd eterminesc overagef or anticancera gentsu sing 1o f2 pathways:t heym aken ationald overaged eterminations( NCDs) or localcoveragedeterminations(LCDs)throughlocal CMScontractors.C MS will oftenu se theN CD pathwayi fat echnology, drug or biologic,d evice,o ro ther medicale ntityi so rw ill be a significantb urdeno nt he Medicare program. Factorsl ikeh igh patientv olumeo rs ignificantc ost mayi nfluence ad ecisiont o developa nN CD to outline coverage provisions.C MS will also consider developing NCDs if treatmentassociatedwithatechnology, drug,ordevicevarieswidely. In thecaseofCRC,clinicians andp atientsh ave thec hoice of numerous treatmento ptions andtherapeutic alternatives,and additional therapiesare in premarketingstagesoftesting. Consideringthese reasonsaswellas thecurrent andexpected future burden of CRConthe Medicare system,i tb ecomes clearerw hy Medicare elected to embark on theNCD pathwayfor themanagementofCRC.Thisisdiscussed in detail below.
Thes econdp athway t oc overage, theL CD, is throughl ocal contractorsw ho oftens ubsequentlyp ost theird ecisions,w hich areb ased on either FDA-approvedi ndications or theo ff-label rulesd escribed previously.L ocal contractorsp ubliclyp ost LCDs andc overageb ulletinst ot heir Webs ites forp roviders andp atientst or eference andu nderstandc overagep olicies determined usingt hism ethod. References basedo np reviously reviewed requests forc overagea re also useds ystematicallyt o make case-by-case coverage determinations.
■■ AHistory Lesson:CRC andCMS
TheNCD process is quiteinvolvedand time-consuming;ittakes months to yearst oc omplete, butt he focus is to methodically evaluate evidence thatwill be usedt od evelop consistent coveragep oliciesf or health technologies.O bvious andl ong-standing concerna bout CRCp rompted CMSt oo pena nN CD review process foroxaliplatin in February2003. This wasallowed under CMS's authorityt op rovide provisionalc overagef or products andt herapies usingt he coverage with evidence determination (CED)p rotocol( whichi sd iscussed more thoroughlyb elow). As additional medications became available to treatC RC,C MS expanded thes cope of theirN CD developmente fforts into the entirety of CRCr athert hani nto1d r ug alone, ands pecifically into off-labelusesofparticulardrugs within theCRC arena. They included irinotecan in theongoing process in May2003and the biologicsbevacizumab andcetuximab in September 2004. 5 TheF DA's "FastT rack"d esignation process also addresses certaino ncologyp roductsw hent he combinationo fap roduct andac laim reveal an unmetm edical need.T he FDAp rocess also allows agents to undergo "PriorityR eview"-reducingt he expected review time from 10 months to about 6m onthsor "Accelerated Approval"-when apromisingproduct is intended forlife-threateningdiseases. Hence, theseproductsbecomeavailable commercially on theb asis of preliminarye vidence prior to formal demonstrationofpatient benefit. 6 Note thatthe FDAbases itsdecisions on safetyand efficacy in productclaims. CMS then acceptsthe FDAdecisions to approve products before allowing them to come to market.H owever, CMS'sa pprovald oesn ot address itsr esponsibility to provide coverage policies intendedt oe nsuret hatp roductsa re used basedo n" reasonable andn ecessary" criteria.T hese arer elated yetd ifferentm issions thatt he FDAa nd CMSo wn.C MS hasa responsibility to providebeneficiaries access to thenewest products andtherapies,b ut it also has theresponsibility of ensuring thata dequatee videncee xistst od esignate theset herapies as "reasonable andn ecessary" within thec onditions fortreatment. At times, basedonthe speedofmarketapprovaland thepopulationsinwhich products mayhave been tested as part of theFDA approvalp rocess,s uche videncem ay be lacking( e.g.,i fa gents navigate an expedited review process at theFDA).
As part of theN CD development process,a nd fort he first time regardingdrugtherapy,CMS formally instituted andbegan providingcoverage forproductsused in off-labelsituat ions while it evaluatedclinicalevidence; beneficiaries were grantedcoverage only if they were involved in clinicalt rialss anctionedb yC MS. By doingso, clinical evidence wassystematicallyand consistently collected andusedtodevelop theNCD over time.
This process is aC ED plan. 7 CMSh ad appliedC ED plans previously;inall cases, theprocess made headline news. Thefirst examined lung volume reductionsurgery in patients with severe emphysema.T he agency sought evidence to identify patients whow ould trulybenefit from thesesurgeries.Othersa ddressed theu se of positron emissiont omography scansf or Alzheimer's disease; bariatrics urgery forp atientso lder than6 5y ears;a nd expandingc overageo fi mplantablec ardioverterd efibrillators. When Medicare usesthe CEDprocess to make coverage decisions, it is ab urdeni na nd of itself. Some concerns includet he costs of thep rocess,t he provisiono ft rial medication data collection activitiesa nd analyses,a nd potentiale thical repercussionso f requiringparticipation in this clinicalevidencecollectionprocess forcoverage. Theseissueshave and will continue to be discussed in public forums.
ForC RC,t he CEDa nd NCDp rocesses allowed foral arge number of therapeuticoptions,and themilieu hasbeenchanging very quicklya sm oreo ptions continue to becomea vailable. In January2 005, aftera lmost 2y ears,C MS produced itsN CD foro ff-label useso fCRC therapies. TheN CD process is lengthy and, as in many diseases,t he optionsf or treatingC RC are changing so quicklythattaking2years forthese review processes mayb et oo slow.C MS and policy makers will continue to evaluate theneedand utility of thesep rocesses,balancing them with theresources required.
■■ TheChangingFaceofMedicarePartB
What has patientexperiencebeenasdrugcostscontinue to rise? This is aq uestiont hath as weighedh eavily on all stakeholders' mindsoverthe last fewyears,and especiallysince Part Dimplementation. Patientshave encounteredsomeverydifficultissues, andthe market has respondedindifferentways.
In theU nitedS tates, thei ssue of drug costsh as recently takeno nm orep olicys ignificance.I n2 006, CMSi ntroduced theconceptofbasingprovider-administered productreimbursement on average sales price(ASP). Untilthen, average wholesale price( AW P) wasm ost commonly usedt od etermine provider reimbursementf or provider-administered products.C MS's goal wast oc reateam arket-baseda pproacht or eimbursement with thep resumption thatt his wouldd ecreaseM edicarep rogram spending.Specifically, theASP-based formulahas accomplished this.H owever,s ignificanta dministrativei ssuess till exist for providers. Areb onaf ides ervice fees included in ASPc alculations? Howi sA SP calculated forn ewly approved medications? Hows houldm edications bundledt ogetheri nc ontracts be addressed?C learly,f urther clarificationa bout ASPc alculations is necessary. Thesei ssuesa re crucialf or providerss ince medication-based reimbursement is still al arge par to ft heir overallpatient care equation
Theirconcernisvalid.CMS announced changesproposedfor 2007 in August 2006,and thecomment per iodendedinOctober 2006.Manystakeholdershave rallied againstthe proposed 5.1% reductioni nt he physician fees chedule; it is larger thanp redicted,and argumentshave been made that it is inappropriate. Providersc laim thatt his reductionw ill severely affect their ability to provideq uality care t ot heir patients.A dditionally, CMS's 1-year oncology demonstrationp roject (a programt o gather specific information relevant to cancerp atients' quality of care,i ncluding theirt reatments, thes pectrumo fc aret hey receive from theirdoctors,and whetherthe care represents best practices) expiresatthe endof2006. This couldcost providersan additional $150 million in thereductionsrealizedin2 006. The demonstrationp roject helped minimize some of thosefinancial effectsoflower physician-officereimbursement forservices, and provided incrementalpayment formedications andtheir administrationt op atients. What will follow,a nd thee ffectsp atients will experience,are nowuncertain.( SeeUpdatesection)
Thei ssue of beneficiary out-of-pocketc ostsc ontinuest ob e important-more so as patiento ut-of-pocketr esponsibilities increase.Aspricesfor drugsincreases,patient premiums,deductibles, andcopaymentsalsorise. Forphysician-office-basedcare, Medicarepays80% of itsallowable feefor office visits andmedicationsa dministeredb yp roviders,l eaving ther emaining 20%, andt he annual deductible,a st he beneficiary's responsibility. To illustrateh ow a2 0% copaymentc an be burdensome for patients,consider an exampleof1CRC treatment: bevacizumab (340 mg)and 2hours of infusionwill cost thepatient $497.49, plus their$ 124a nnualP artBd eductiblea nd $88.50 monthly Part Bpremium.Notethatthe annual Part Bpremium becomes income-indexedi n2 007. 8 Medicarep ays$ 1,989.95 fort he medication dose andadministrativefee forgivingthe treatment. As theseP artB -covered products area pproveda nd reacht he market with unprecedentedp rice tags,i ntense scrutinyo f Medicare benefitsa nd medicalc ostsw ill surely follow.T he health care indus trya nd them arketplace aren ow dealing with theb urdeno ff inding ways to ensure that out-of-pocket responsibility is notabarrier to health care access.( SeeUpdate section) ■■ Medicare Part D ThebasicsofPartDare familiar to most managedcarepharmacistsb yn ow.B eneficiaries have ad iverse arrayo fp rescription drug plan (PDP)sponsorsand Medicare-Advantage prescription drug (MA-PD)p lan sponsorsf romw hich to choose.T he available MA-PDplans offeredin2006neared1,900.AsofJune2006, theHHS reported that 22.5 million beneficiaries hadenrolledin Medicare Part D. Many chronicallyi ll beneficiaries reacht he "donut hole"d uringt he thirdq uartero ft he year andt huswill likely bear thefullbrunt of thecoveragegap responsibility.(Forall patients,Medicarecovers75% of thefirst $2,250 worth of drugs, butafter that,coveragedrops to zero andonlyresumes when the beneficiary reaches $5,100 in out-of-pocketexpenses. Then,f or most patients,M edicarep ays9 5% of costs. Thea pproximately $3,000 gapi nw hich patients must payt he entirety of drug costsi sc alled thed onut hole.) Because chronicallyi ll patients typicallyh ave ap rofile that includes many medications,i ti s importanttoconsider notonlyindividualmedications andtheir associated costsbut also all medicationsand theircollectivecosts in thedonut hole conundrum. Thevastmajority of PDPs arenot offering coverage throught he donuth olei n2 006. Individual plans' sponsorsh ave considerable latitude in this matter,h owever, ands omep lansd oo ffer coverage. CMS data suggestt hat only 2% of plansc over brandedand genericp roductsand 13% coveronlygeneric drugsthroughthe donuthole.
The2006average monthlypremium forbeneficiaries enrolled in Part Dw as about $37, andi ti sl ikelyt ob es lightlyl ower in 2007.Althoughexperts expected that most planswould require as tandardd eductibleo f$ 250, only 34%o fp lans actuallyd id. Many plans( 58%) have no deductible.N otethatthis wasq uite different from what CMSp rovideda st he models tructure, knowingt hati ndividualp lan sponsorsh ad thea utonomy to developand provideplandesigns that were actuariallyequivalent to thestandardstructure. 9 Specialtyd rugs deserves eparate discussion,e speciallys ince many antineoplastics arec onsidered specialtyd rugs.M ost formularies have,u ntil now, included specialtyd rugs ande xpensive therapiesi nt he higher (third andf ourth) tiers. That trend continuedi nP artDf ormularies,w herein more than 90%o f planshave tiered structures anda pproximately 6% of drugsfall into thef ourthtier. Much to thes urpriseo fmany, some Part D formulariesspecificallylistedmedications that arePartB-eligible. Medicare is in thep rocess of issuing guidance for2 007, andi t will includes pecificl anguagec oncerning specialtyp roducts (e.g., products thath ave negotiatedp ricese xceeding $500 per monthw ill be placed in as pecialty tier andb ec overed with a coinsuranceo f2 5% or less). This is thef irst time that CMS's involvement hasr eached thel evel of telling plan s ponsorsh ow they must manage thosep roducts. Cancerp atientsw ill need to evaluate formulariesv eryc arefully as they select their2 007 Part Dplan.
Many expertsa ttempted to estimate howmanybeneficiaries wouldhit or surpassthe donutholein2006. Medicare designed thedonut hole as ariskmanagementtool, so beneficiaries would sharer esponsibility in theiro verall medication management costs. TheK aiser Family Foundation originallye stimated in 2004 that2 4% of beneficiaries woulde xperienceo ut-of-pocket spending within thed onut hole.R ecentf igures,h owever,i ndicate that3 5% of Medicareb eneficiaries reachedt he donuth ole by August 2006 andt hato ft hose,1 6% wouldd iscontinue treatmenta ll together. 10 Patientsw ho areo nr elativelyi nexpensive maintenancem edications mayn ot b ea sl ikelyt of eelt he dramatice ffectso ft hiso ut-of-pocket responsibility,b ut those taking more expensivet herapies such as oral cancerp roducts arel ikelyt or each thed onut hole more quickly, some even as earlyasFebruary.
Currently, as exceptions to Medicarel aw,M edicareP artB covers select oral antineoplastics, because they arec onsidered prodrugs.F or example, thefluorouracilp recursorc apecitabine is oneo ft hese Medicare Part B-coveredd rugs.O ther products frequentlyu sedi nt he cancerp opulationa re provideradministered (e.g., injectables, infusables) anda re Part Bcovered, both as antineoplasticsa nd supportive care products such as hemopoetic agents,a ntiemeticp roducts, ands ome antinausea agents.I ti si mportant to note that cancerp atients oftenh ave an armamentariumo fo ther medications usedi n theiro verall cancerm anagement plans, such as oral or selfadministered therapiesu sedf or pain management andm ental health.These agents play asignificantroleinthe care of cancer patients,a nd they aren ot coveredu nder Part B, butr ather Part D.
In a2 004e ditorial in the NewE nglandJ ournal of Medicine, DeborahS chrag, MD,s ummarizeds omeo ft he cost concerns specifically related to CRC.
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Shetracedthe progress of chemotherapeutica gentsf romt he 1960s,w henf luorouracilw as the primaryc hemotherapeutica gent available to treatC RC,t ot he 1990s,w hent he FDAb egan to approve what wast hen5n ew agents (irinotecan,o xaliplatin,c apecitabine, bevacizumab, and cetuximab) fort hisi ndication. These therapiesi mproveds urvivalfromameanof8monthswithout treatmentto12months with flourouracil.A fter 2002,m edians urvivali ncreased to 21 months with use of theneweragents, andlengthier survivals areexpected as data from ongoingtrialsiscollected.Doublingthe median survival increasedthe cost of therapy340 times, based on AW P-as taggeringf igure. Note thatt hisf igured oesn ot accountf or theincreased cost of simply living longer andbeing able to receive more cycles of therapy; it is basedo nan8-week treatmentplan. Thecost of managing metastases andsubsequent tumors is also notc onsidered in this editorialc omment. This is av eryr eal examp le of howc ostso fcaref or CRCare increasing at ratesthatare significantand especially meaningful forpatients as they ares haring thef inancial burden of receiving this care and, at times, with benefitsthatare beingpubliclydebated.
As prices continue to rise,a nd lifee xpectancy increases, Medicare CRCp atientsw ho lack supplemental coverage face tremendous financial challenges;theycould accrue billstotaling 20%o ft he cost of treatment indefinitelyb ased on therapies coveredv ia Medicare Part B. Accordingt oM edicareP ayment Advisory Commission (MedPAC),approximately 9% of Medicare beneficiaries have no source of supplementalcoveragetoalleviate this financial burden. Some physiciansh ave continuedt ot reat patients in theiro ffices,d espite thep atients' inability to meet thec ost-sharing requirements.T he res ulth as been af inancial liability fort he practice.C ostsa ssociatedw ithn ewer,i nnovative therapiesw ill likelyi mpactc hoicesr egarding therapyf or cancer. Althoughn ewer therapiesm ay have fewers idee ffects andi mprovedr emissiona nd survival rates, thec ost of care is considerably higher.Patientsand theoncologists whotreat them areleftwithverydifficultdecisions,including uncertaintyabout responset otreatment thatwill mimicthe efficacy ratesinclinicalt rialsa nd theh ighc ost of then ewerd rugt herapy options. Manypractices,havingincurredaliability by continuing to treat beneficiaries whoc annotm eett he cost-share,a re beginningt o counselp atientsb eforet reatment about ther eal or potential financial burden. 12 Butincreasingly, theconcernisnot only theuninsured butalso theunderinsured:patientswho have coverage,but cannotafford theiro ut-of-pocket responsibilities.M anufacturer-sponsored patientassistanceprogramshave traditionallyoffered coverage to uninsuredp atients. More recently, copaymenta ssistance foundations-bona fide,i ndependent charities, oftenc alled" costsharinga ssistancem odels" or "copay assistance foundations"-have enteredthe health care milieu to provideassistance.CMS andt he Office of theI nspector Generalh ave reviewed and endorsedthis new modeland developedaset of rulesand guidelinesbywhich thesefoundations must be developed andadministered. Thesef oundations do notp rovide drug-specifica ssistancebut,rather, assistance across diseasestateswithout regard to specific products or manufacturers. Monetary donationsfrom pharmaceutical manufacturersa nd otheri nterestedg roupsa re pooled andd esignatedf or specific diseasec ategories; patients with high-burdend iseasest hens eekf unding from this pool. Manyf oundations aref ocusingo nC RC (Table 2) andf inding ways to assist CRCpatientswithout-of-pocketrequirements.
■■ Summary
CMS,v is-à-vis theM edicarec overagep rocess,i se xamining andi mplementingw ayst oc ontinue providinga ccess to therapies as thee videncea bout safety,e fficacy, ande ffectiveness accumulates. Over time,p ublicp olicym akersa nd Medicare will have to make decisionsabout thesustainability of thepath they have chosen from financial,policydevelopment, andoverall burden standpoints. Thep rivate industry's involvementi n thesep rocesses will need to be assertiveand forward-thinking, especiallya se xpensive oral products become am orer outine treatmentchoice. Patients' out-of-pocket expenses will forceour health care systemstolookfor ways to ensure continuing access to therapiesand reduce financial burdensasacause forn onadherence, therapycessation, andchangingtreatment decisionsby providersand patients.
■■ Update
Thef ollowing is information regardingd evelopmentss ince the October symposiumrelevanttothe previous discussion.
Medicare PhysicianFee Schedule
TheM edicareP hysician FeeS chedule( MPFS)f inal rule was released November 1, 2006 .A ccording to thef inal ruling, whichbecamee ffectiveJ anuary1 ,2 007, theM edicarep rogram substantiallyincreased workvaluesf or Evaluation andManagement (E&M)Services-effectivelyreimbursing physiciansmore fort he time they spendt alking with Medicare beneficiaries about theirh ealth care.T he ruling also mandated reimbursement forand measures to eliminatebarriersf or ab roader range of preventive services,i ncluding exemptingt he cost of the colorectal screeningfromPartBdeductible.
Althoughthe December ruling wastoimplementa5%cut in physician payments andreducethe conversion factor,Congress's December 9, 2006,passage of theTax Relief andHealth CareAct overrode thesedirectives,placing amoratoriumonthe cuts until theend of 2007.
Ther ulingm aintainedt he currentr eimbursement rate of ASP+6%for Part Bdrugs administered in outpatientfacilities. It did, however, clarifyoraddress some outstanding ASPtechnical issues. 13 Newdrugs arepaidat106%ofthe wholesaleacquisition 20 Onlya bout 12%o f those beneficiaries hadd rugp lanst hath elpedw ithc ostsi nsidet he donuthole, andabout 60%ofthese beneficiaries hadplans that coveredo nlyg eneric drugs. Of 266c ompanies offering donut hole Medicare drug plansin2 006, 10 accountedf or 72%o fthe market.
In 2007,8 5% of plansa re offering comprehensivec overage, whichincludesthe so-calleddonut hole coverage gap. Still,most (about 85%) of thesep lans providingg ap coverage only cover genericdrugs.And theaverage generic-only gapcoverage monthly premiumi s$ 51.11c ompared with then o-gapp olicyp remium of $30.17.Brand/generic gapcoveragepremiumssoarmorethan 3-fold higher than theno-gapcoverageat$93.46.
More recentattention hasbeenonthe societal implications of thegeneric-only provisions of privateinsurance "gap"coverage.
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Some beneficiaries,suchasthose with multiple sclerosisorrheumatoidarthritis,musttakebrand-namedrugs because thereare no generica lternatives. LasV egas-based Sierra Health Services, theonlymajorplantocover brand-name drugsinthe "gap"this year,r eportedlyl ost $3 million in the firstm onth of operation andwas forced to ceaseits brand-name coverage option for2008. Humana hadas imilar experience in 2006 when it triedt o coverb rand-named rugs in itsg ap policy.T hese experiences areo nlyl ikelyt or einforce plan decisionst oc ircumventt he societal need fore xpandedg ap coverag ef ormularies inc ertain patientpopulations. Thosep hysiciansw ho satisfactorily submit data will receive ap ayment equal to 1.5% of alla llowed chargesf or thep eriod betweenJ uly1 ,2 007, andDecember3 1, 2007,subject to acap. An aggregatedollaramountof$ 1.35 billion is thelimit for2008. Thepaymentfor 2007 will be a1 -time, lump-sum,after-the-fact payment. Claims maybesubmittedthroughthe endofFebruary 2008 fors ervicesr endered during ther eportingp eriodand the paymentwill notbeforthcoming untilafter thattime.
On April3,2007, CMS released detailed specifications forthe 74 measures included in the2007PQRI. Foracomplete listingof specifications visith ttp://www.cms.hhs.gov/PQRI/Downloads/ Specifications_2007-02-04.pdf
